Cxbladder on the Podium at the Annual SUO Meeting in the US

Late last week, at the Annual Meeting of the Society of Urologic Oncology (SUO) in Orlando USA, urologists at UCSF presented their findings on the use of Cxbladder Monitor (CxbM) in a real-world setting for managing patients during COVID-19.

The SUO Annual Meeting is attended by urologists from around the world and these findings reinforced Cxbladder Monitor’s value, noting that “CxbM was feasible and safe for patients on surveillance for non-muscle invasive bladder cancer (NMIBC) and decreased frequency of cystoscopy“ …and “CxbM may be used to further risk stratify patients to deintensify surveillance for NMIBC during the COVID-19 pandemic and beyond.”

Of importance, based on Cxbladder Monitor test results, urologists were able to accurately determine whether further investigation, including an invasive cystoscopy procedure was required.

• 67% of patients had a low probability Cxbladder Monitor score and had their surveillance cystoscopy deferred to their next visit at either 3, 6 or 9 months, with no notable detections of NMIBC in this group at their subsequent visit.
• One third of patients tested positive to Cxbladder Monitor and 82% of these patients were scheduled for immediate cystoscopy, with 50% of those patients requiring a biopsy and further workup.

The findings provide strong validation for Cxbladder’s use when cancer patients might either be unable to come to a clinic in a risky pandemic setting, or when they live in a rural location or an area distanced from a clinic. This real-world clinical evidence highlights the positive outcomes for both the clinic and patient alike, providing further support for guidelines inclusion.

For further details, please refer to this link.